Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis

Registry ID
EUCTR2014-004919-36
Source registry
EUCTR
Phase
PHASE3
Sponsor
Schering-Plough Research Institute, a Division of Schering Corporation
Last update
2026-08-16

Conditions

Summary

The primary objective of this study was to assess the efficacy in relieving the symptom of nasal congestion with MFNS 200 mcg given once daily compared to placebo in subjects with symptomatic SAR.

View on source registry